vaccines against hiv-aids: 2011 - ix jornada de promoci³ de la
TRANSCRIPT
![Page 1: VACCINES AGAINST HIV-AIDS: 2011 - IX Jornada de promoci³ de la](https://reader031.vdocuments.us/reader031/viewer/2022012011/613d3931736caf36b75ac863/html5/thumbnails/1.jpg)
![Page 2: VACCINES AGAINST HIV-AIDS: 2011 - IX Jornada de promoci³ de la](https://reader031.vdocuments.us/reader031/viewer/2022012011/613d3931736caf36b75ac863/html5/thumbnails/2.jpg)
VACCINES AGAINST HIV-AIDS: 2011
1. General considerations
2. Therapeutic vaccines against HIV. Dendritic cells
3. Preventive vaccines against HIV. Other strategies for prevention
4. Final considerations
![Page 3: VACCINES AGAINST HIV-AIDS: 2011 - IX Jornada de promoci³ de la](https://reader031.vdocuments.us/reader031/viewer/2022012011/613d3931736caf36b75ac863/html5/thumbnails/3.jpg)
7000 M 30 M + (85% in developing countries)
Preventive vaccine ART for life Eradication Therapeutic vaccine (functional cure)
Per year: > 600 Catalunya >3000 Spain > 3 M World
![Page 4: VACCINES AGAINST HIV-AIDS: 2011 - IX Jornada de promoci³ de la](https://reader031.vdocuments.us/reader031/viewer/2022012011/613d3931736caf36b75ac863/html5/thumbnails/4.jpg)
VACCINES AGAINST HIV-AIDS: 2011
1. General considerations
2. Therapeutic vaccines against HIV. Dendritic cells -Functional cure 3. Preventive vaccines against HIV. Other strategies for
prevention
4. Final considerations
![Page 5: VACCINES AGAINST HIV-AIDS: 2011 - IX Jornada de promoci³ de la](https://reader031.vdocuments.us/reader031/viewer/2022012011/613d3931736caf36b75ac863/html5/thumbnails/5.jpg)
Wild type
I Res.
R Res.
Z Res.
I
I
I+R+P
![Page 6: VACCINES AGAINST HIV-AIDS: 2011 - IX Jornada de promoci³ de la](https://reader031.vdocuments.us/reader031/viewer/2022012011/613d3931736caf36b75ac863/html5/thumbnails/6.jpg)
THERAPEUTIC VACCINE AGAINST HERPES ZOSTER Vaccines againts rabies, tetanus and difteria are therapeutic
![Page 7: VACCINES AGAINST HIV-AIDS: 2011 - IX Jornada de promoci³ de la](https://reader031.vdocuments.us/reader031/viewer/2022012011/613d3931736caf36b75ac863/html5/thumbnails/7.jpg)
5
50
500
5000
50000
500000
5000000
5 10 15 20 25 30 35 40 45 50 55 60
months
pla
sm
a v
iral
load
HAART STOP HAART TV
![Page 8: VACCINES AGAINST HIV-AIDS: 2011 - IX Jornada de promoci³ de la](https://reader031.vdocuments.us/reader031/viewer/2022012011/613d3931736caf36b75ac863/html5/thumbnails/8.jpg)
The immune system is not able to “contain” VL rebound even after a long term successful suppressive ART Conversely, the aim of an immunogen or a therapeutic vaccine should be to avoid VL rebound after interruption of ART
![Page 9: VACCINES AGAINST HIV-AIDS: 2011 - IX Jornada de promoci³ de la](https://reader031.vdocuments.us/reader031/viewer/2022012011/613d3931736caf36b75ac863/html5/thumbnails/9.jpg)
VACCINES AGAINST HIV-AIDS: 2011
Therapeutic vaccines against HIV infection Felipe García, Agathe León, Josep M Gatell, Montserrat Plana, Teresa Gallart Hospital Clinic-HIVACAT, IDIBAPS, University of Barcelona. Barcelona. Spain Correspondence to: Dr. Felipe García, Infectious Diseases Unit, Hospital Clínic, Villarroel, 170, 08036 Barcelona, Spain. Phone: 34932275586, FAX: 34934514438, E-mail: [email protected]; Acknowledgments: This study was partially supported by grants: FIS PS09/01297, TRA-094, EC10-153, FIS PI10/02984, SAF2006-26667-E, RIS*, HIVACAT**, ORVACS***. Dr Felipe García was recipient of a Research Grant from IDIBAPS****, Barcelona, Spain. Dr. M Plana was supported by contract FIS 03/0072 from the Fundació Privada Clínic per a la Recerca Biomèdica in collaboration with the Spanish Health Department
![Page 10: VACCINES AGAINST HIV-AIDS: 2011 - IX Jornada de promoci³ de la](https://reader031.vdocuments.us/reader031/viewer/2022012011/613d3931736caf36b75ac863/html5/thumbnails/10.jpg)
VACCINES AGAINST HIV-AIDS: 2011
Modalities of therapeutic vaccines tested in clinical trials -Whole inactivated virus: 1
-Subunit vaccines: 4
-Vaccines using DNA as vector: 4
-Viral vector vaccines: 12
-Dendritic cells based vaccines: 2
![Page 11: VACCINES AGAINST HIV-AIDS: 2011 - IX Jornada de promoci³ de la](https://reader031.vdocuments.us/reader031/viewer/2022012011/613d3931736caf36b75ac863/html5/thumbnails/11.jpg)
HIVACAT Second Period HIVACAT Current Period
2012 2013 2014 2015 2016 2011
Timelines Therapeutic Vaccines
11
DCV2 DCV2 2nd arm & trial data
Development of pNL4.3/ΔRT/ΔGag chimeras
Δ-RT/ Δ-Int +/- chimeras
Phase I clinical trial & data analysis MVA/chimp-adeno
In vitro production & characterization of NL4.3/ΔRT virions & chimeras NL4.3/ΔRT/ΔGag NL4.3/ΔRT/ΔNef, NL4.3/ΔRT/ΔEnv
Development of safe recombinant chimeras Nef & Env and double
chimeras
Characterization , immunogenicity studies & analysis
DCV trial development
RISVAC03- MVA Phase I clinical trial & trial data
Phase II clinical trial
DCV3 & trial data DCV3
![Page 12: VACCINES AGAINST HIV-AIDS: 2011 - IX Jornada de promoci³ de la](https://reader031.vdocuments.us/reader031/viewer/2022012011/613d3931736caf36b75ac863/html5/thumbnails/12.jpg)
ORVACS
MANON 03 STUDY
![Page 13: VACCINES AGAINST HIV-AIDS: 2011 - IX Jornada de promoci³ de la](https://reader031.vdocuments.us/reader031/viewer/2022012011/613d3931736caf36b75ac863/html5/thumbnails/13.jpg)
HAART
Pulsed DC (4x106 virions/vaccine)
PLASMAPHERESIS
CD4>500 cells/microL PVL>5000 copies/ml
-w246
PVL<20
-w90
w0 6w 12w 18w
-d8 -d8 -d8
STOP-2
w30
-d8
STOP-1
HAART
-w78
Blood sample (60-80 ml)
for DC generation
HAART PLUS THERAPEUTIC VACCINE WITH AUTOLOGOUS MONOCYTE-DERIVED
DENDRITIC CELLS (DC) LOADED WITH INACTIVATED AUTOLOGOUS HIV-1
-d8
24w
Non-Pulsed DC
s.c. DC injections
CASES N=12
CONTROLS N=6*
HAART
PVL<20
HAART *2 lost for follow-up
![Page 14: VACCINES AGAINST HIV-AIDS: 2011 - IX Jornada de promoci³ de la](https://reader031.vdocuments.us/reader031/viewer/2022012011/613d3931736caf36b75ac863/html5/thumbnails/14.jpg)
0 2 4 6 8 10 12 14 16 18 20 22 24 260.0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
4.0
4.5
5.0
5.5
stop1
stop2
Weeks after HAART interruption
log
10 o
f p
lasm
a v
iral
load
(co
pie
s/m
l)
Patient #262
0 2 4 6 8 10 12 14 16 18 20 22 24 260
1
2
3
4
5
6
Stop 1
Stop 2
WEEKS AFTER HAART INTERRUPTION
Patient #207
0 2 4 6 8 10 12 14 16 18 20 22 24 260
1
2
3
4
5
6
Stop 1
Stop 2
WEEKS AFTER HAART INTERRUPTION
log
10 o
f p
lasm
a v
iral
load
(co
pie
s/m
l)
0 2 4 6 8 10 12 14 16 18 20 22 24 260.0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
4.0
4.5
5.0
5.5stop1
stop2
Weeks after HAART interruption
log
10 o
f p
lasm
a v
iral
load
(co
pie
s/m
l) Figure 3D Figure 3C
Figure 3B Figure 3A
Cases: n=12
Controls: n=4
DCV-1 study
![Page 15: VACCINES AGAINST HIV-AIDS: 2011 - IX Jornada de promoci³ de la](https://reader031.vdocuments.us/reader031/viewer/2022012011/613d3931736caf36b75ac863/html5/thumbnails/15.jpg)
HAART Stop HAART
-72 -32 -24 0 2 4 6 8 10 48 WEEK
Inclusion criteria
1. <20 copies/ml
2. Nadir >350 C
CD4+ T c/mm3
Doses of pulsed MD-DC
STOP 1
Virus culture
STOP 2
ARM III (N=12)
ARM V
CONTROL
GROUP (N=12)
Doses of NON- pulsed MD-DC
ARM IV (N=12)
-d7 Blood sample (120 ml)
for DC generation
Doses of pulsed MD-DC
DCV2-b study
![Page 16: VACCINES AGAINST HIV-AIDS: 2011 - IX Jornada de promoci³ de la](https://reader031.vdocuments.us/reader031/viewer/2022012011/613d3931736caf36b75ac863/html5/thumbnails/16.jpg)
DCV-2b study (submitted)
![Page 17: VACCINES AGAINST HIV-AIDS: 2011 - IX Jornada de promoci³ de la](https://reader031.vdocuments.us/reader031/viewer/2022012011/613d3931736caf36b75ac863/html5/thumbnails/17.jpg)
• __ ______ _________ __ _____ ____ __ ____ __ ___ ___ __________ _ ____ ________ __ _____ ___ _______ ___ ___
• __ ____ _________ ___ ___ ________ _ ___ ___ ___ ___ ______ ___ • ____ ___ __ ___________ ____ ___ ______ __ _____ ____ __ ____ __ ___ ___
___________ __ __________ _______
Figure 5. Pre-ART vs. Week 12 of STI Log Change in Viral Load
-6,00
-5,00
-4,00
-3,00
-2,00
-1,00
0,00
1,00
2,00
Log C
hange in V
iral L
oad
___ _________ __ _____ ____ ___ __________ _ __ ___
Routy et al.
![Page 18: VACCINES AGAINST HIV-AIDS: 2011 - IX Jornada de promoci³ de la](https://reader031.vdocuments.us/reader031/viewer/2022012011/613d3931736caf36b75ac863/html5/thumbnails/18.jpg)
5
50
500
5000
50000
500000
5000000
5 10 15 20 25 30 35 40 45 50 55 60
months
pla
sm
a v
iral
load
HAART STOP HAART TV
![Page 19: VACCINES AGAINST HIV-AIDS: 2011 - IX Jornada de promoci³ de la](https://reader031.vdocuments.us/reader031/viewer/2022012011/613d3931736caf36b75ac863/html5/thumbnails/19.jpg)
VACCINES AGAINST HIV-AIDS: 2011
1. General considerations
2. Therapeutic vaccines against HIV. Dendritic cells -Discordant CD4 response ? -Eradication (ERAMUNE study) ? -Reduce reservoirs (ERAMUNE study) ? -Minimize inflammation / immune activation ?
-Minimize needs of ART ?
3. Preventive vaccines against HIV. Other strategies for prevention
4. Final considerations
![Page 20: VACCINES AGAINST HIV-AIDS: 2011 - IX Jornada de promoci³ de la](https://reader031.vdocuments.us/reader031/viewer/2022012011/613d3931736caf36b75ac863/html5/thumbnails/20.jpg)
Patients off HAART
-6 0 2 4 48 WEEKS
Inclusion criteria
1. > 10000 c/ml
2. Nadir >350
CD4+ T c/mm3
1st 2nd 3rd doses of
pulsed MD-DC
VIRUS
CULTURE
ARM I (N=12)
ARM II
CONTROLS
(N=12)
-d7 Blood sample (120 ml)
for DC generation
1st 2nd 3rd doses of
non-pulsed MD-DC
PART 1
Garcia F et al. JID, 2011
![Page 21: VACCINES AGAINST HIV-AIDS: 2011 - IX Jornada de promoci³ de la](https://reader031.vdocuments.us/reader031/viewer/2022012011/613d3931736caf36b75ac863/html5/thumbnails/21.jpg)
0 4 8 12 16 20 24 28 32 36 40 44 48-0.4
-0.2
0.0
0.2
0.4
DC-PLACEBO
DC-HIV-1
DC-PLACEBO 12 12 12 12 11 11 11 9DC-HIV-1 10 10 10 10 8 8 8 7
0.08
0.03
0.04
AUC,
P= 0.06
WEEKS
Lo
g 10
PVL
(cop
ies/
ml)
VIRAL LOAD RESPONSES
IT WAS OBSERVED A MODEST DECREASE OF VL IN VACCINATED PATIENTS
![Page 22: VACCINES AGAINST HIV-AIDS: 2011 - IX Jornada de promoci³ de la](https://reader031.vdocuments.us/reader031/viewer/2022012011/613d3931736caf36b75ac863/html5/thumbnails/22.jpg)
5
50
500
5000
50000
500000
5000000
5 10 15 20 25 30 35 40 45 50 55 60
months
pla
sm
a v
iral
load
Therapeutic vaccine
![Page 23: VACCINES AGAINST HIV-AIDS: 2011 - IX Jornada de promoci³ de la](https://reader031.vdocuments.us/reader031/viewer/2022012011/613d3931736caf36b75ac863/html5/thumbnails/23.jpg)
5
50
500
5000
50000
500000
5000000
5 10 15 20 25 30 35 40 45 50 55 60
months
pla
sm
a v
iral
load
Therapeutic vaccine
Less ART ? Later ART ?
![Page 24: VACCINES AGAINST HIV-AIDS: 2011 - IX Jornada de promoci³ de la](https://reader031.vdocuments.us/reader031/viewer/2022012011/613d3931736caf36b75ac863/html5/thumbnails/24.jpg)
7000 M 30 M + (85% in developing countries)
Preventive vaccine ART for life Eradication Therapeutic vaccine (functional cure)
Per year: > 600 Catalunya >3000 Spain > 3 M World
![Page 25: VACCINES AGAINST HIV-AIDS: 2011 - IX Jornada de promoci³ de la](https://reader031.vdocuments.us/reader031/viewer/2022012011/613d3931736caf36b75ac863/html5/thumbnails/25.jpg)
VACCINES AGAINST HIV-AIDS: 2011
1. General considerations
2. Therapeutic vaccines against HIV. Dendritic cells 3. Preventive vaccines against HIV. Other strategies for
prevention
4. Final considerations
![Page 26: VACCINES AGAINST HIV-AIDS: 2011 - IX Jornada de promoci³ de la](https://reader031.vdocuments.us/reader031/viewer/2022012011/613d3931736caf36b75ac863/html5/thumbnails/26.jpg)
clinicaloptions.com/hiv
HIV/AIDS Highlights From Rome
Efficacy of HIV Prevention Strategies From
Randomized Clinical Trials
Abdool Karim SS, et al. Lancet. 2011;[Epub ahead of print].
100 0 20 40 60 80
Efficacy (%)
Study Effect Size, % (95% CI)
ART for prevention; HPTN 052, Africa, Asia, Americas
PrEP for discordant couples; Partners PrEP, Uganda, Kenya
PrEP for heterosexual men and women; TDF2, Botswana
Medical male circumcision; Orange Farm, Rakai, Kisumu
PrEP for MSMs; iPrEX, Americas, Thailand, South Africa
Sexually transmitted diseases treatment; Mwanza, Tanzania
Microbicide; CAPRISA 004, South Africa
HIV vaccine; RV144, Thailand
96 (73-99)
73 (49-85)
63 (21-84)
54 (38-66)
44 (15-63)
42 (21-58)
39 (6-60)
31 (1-51)
![Page 27: VACCINES AGAINST HIV-AIDS: 2011 - IX Jornada de promoci³ de la](https://reader031.vdocuments.us/reader031/viewer/2022012011/613d3931736caf36b75ac863/html5/thumbnails/27.jpg)
VACCINE AGAINST HIV-AIDS: 2005
Most efficient and cost effective intervention in the eradication (small pox, polio) or control of transmisible infectious diseases Most are preventive Some are “therapeutic”: rabies, difteria, tetanus, zoster
![Page 28: VACCINES AGAINST HIV-AIDS: 2011 - IX Jornada de promoci³ de la](https://reader031.vdocuments.us/reader031/viewer/2022012011/613d3931736caf36b75ac863/html5/thumbnails/28.jpg)
VACUNAS: COMPONENTE MAGICO
I.P.
![Page 29: VACCINES AGAINST HIV-AIDS: 2011 - IX Jornada de promoci³ de la](https://reader031.vdocuments.us/reader031/viewer/2022012011/613d3931736caf36b75ac863/html5/thumbnails/29.jpg)
VACCINE AGAINST HIV-AIDS: 2011
Most efective vaccines have been discovered by trial and error without knowing the correlates of immuneprotection of natural disease or to prevent or modify the evolution of the disease
![Page 30: VACCINES AGAINST HIV-AIDS: 2011 - IX Jornada de promoci³ de la](https://reader031.vdocuments.us/reader031/viewer/2022012011/613d3931736caf36b75ac863/html5/thumbnails/30.jpg)
deteccion
análisis
reacción
Anticuerpos no neutralizantes neutralizantes
Células citotóxicas (CD8, CTL´s)
uso diagnóstico
control de la infección vacunas
uso diagnóstico control de la infección rechazo de transplantes vacunas ?
![Page 31: VACCINES AGAINST HIV-AIDS: 2011 - IX Jornada de promoci³ de la](https://reader031.vdocuments.us/reader031/viewer/2022012011/613d3931736caf36b75ac863/html5/thumbnails/31.jpg)
VACCINE AGAINST HIV-AIDS: 2005
Immune system (innate, Ab, CMI, mucosal) is the natural tool to identify, protect, eradicate and/ or modulate the evolution of transmisible infectious diseases After a first contact is able to generate a quick memory response Limited varibility of ofending pathogens. Cross reactivity Remains intact during the course of most infections
![Page 32: VACCINES AGAINST HIV-AIDS: 2011 - IX Jornada de promoci³ de la](https://reader031.vdocuments.us/reader031/viewer/2022012011/613d3931736caf36b75ac863/html5/thumbnails/32.jpg)
deteccion
análisis
reacción
Anticuerpos no neutralizantes neutralizantes
Células citotóxicas (CD8, CTL s)
uso diagnóstico
control de la infección vacunas
uso diagnóstico control de la infección rechazo de transplantes vacunas ?
![Page 33: VACCINES AGAINST HIV-AIDS: 2011 - IX Jornada de promoci³ de la](https://reader031.vdocuments.us/reader031/viewer/2022012011/613d3931736caf36b75ac863/html5/thumbnails/33.jpg)
VACCINE AGAINST HIV-AIDS: 2011
![Page 34: VACCINES AGAINST HIV-AIDS: 2011 - IX Jornada de promoci³ de la](https://reader031.vdocuments.us/reader031/viewer/2022012011/613d3931736caf36b75ac863/html5/thumbnails/34.jpg)
VACCINE AGAINST HIV-AIDS: 2011
![Page 35: VACCINES AGAINST HIV-AIDS: 2011 - IX Jornada de promoci³ de la](https://reader031.vdocuments.us/reader031/viewer/2022012011/613d3931736caf36b75ac863/html5/thumbnails/35.jpg)
VACCINE AGAINST HIV-AIDS: 2011
![Page 36: VACCINES AGAINST HIV-AIDS: 2011 - IX Jornada de promoci³ de la](https://reader031.vdocuments.us/reader031/viewer/2022012011/613d3931736caf36b75ac863/html5/thumbnails/36.jpg)
VACCINE AGAINST HIV-AIDS: 2005
>= 20% variability
![Page 37: VACCINES AGAINST HIV-AIDS: 2011 - IX Jornada de promoci³ de la](https://reader031.vdocuments.us/reader031/viewer/2022012011/613d3931736caf36b75ac863/html5/thumbnails/37.jpg)
Diversidad
![Page 38: VACCINES AGAINST HIV-AIDS: 2011 - IX Jornada de promoci³ de la](https://reader031.vdocuments.us/reader031/viewer/2022012011/613d3931736caf36b75ac863/html5/thumbnails/38.jpg)
Walker B. NEJM. 1998
Pilcher CD. J Clin Invest. 2004.
Etapas tempranas de la infección por el VIH
Captación y transporte del virus
por células dendríticas.
Infección CD4+ en la lámina propia
y ganglios reginales
Diseminación masiva del VIH
-Organos linfoides
-Sistema nervioso central
-Establecimiento de reservorios
-Replicación persistente
-Latencia
2 dias
5 dias
RESPUESTA INMUNE 4-12
semanas
![Page 39: VACCINES AGAINST HIV-AIDS: 2011 - IX Jornada de promoci³ de la](https://reader031.vdocuments.us/reader031/viewer/2022012011/613d3931736caf36b75ac863/html5/thumbnails/39.jpg)
Batalla de Normandia. Instalación de cabezas de puente
6/6/1944
![Page 40: VACCINES AGAINST HIV-AIDS: 2011 - IX Jornada de promoci³ de la](https://reader031.vdocuments.us/reader031/viewer/2022012011/613d3931736caf36b75ac863/html5/thumbnails/40.jpg)
Costa de Normandía: playas de Utha, Ohama, Gold, Juno, Sword
![Page 41: VACCINES AGAINST HIV-AIDS: 2011 - IX Jornada de promoci³ de la](https://reader031.vdocuments.us/reader031/viewer/2022012011/613d3931736caf36b75ac863/html5/thumbnails/41.jpg)
VACCINE AGAINST HIV-AIDS: 2011
x
? ??
![Page 42: VACCINES AGAINST HIV-AIDS: 2011 - IX Jornada de promoci³ de la](https://reader031.vdocuments.us/reader031/viewer/2022012011/613d3931736caf36b75ac863/html5/thumbnails/42.jpg)
VACCINE AGAINST HIV-AIDS: 2011
![Page 43: VACCINES AGAINST HIV-AIDS: 2011 - IX Jornada de promoci³ de la](https://reader031.vdocuments.us/reader031/viewer/2022012011/613d3931736caf36b75ac863/html5/thumbnails/43.jpg)
Viral envelope
gp41
CD4bs
gp120
(Burton D. Human neutralizing antibodies and a vaccine for HIV-1.
XIV International AIDS Conference [Abstract nº201])
dominio de fusión
dominio interacción CD4
![Page 44: VACCINES AGAINST HIV-AIDS: 2011 - IX Jornada de promoci³ de la](https://reader031.vdocuments.us/reader031/viewer/2022012011/613d3931736caf36b75ac863/html5/thumbnails/44.jpg)
> 99 %
![Page 45: VACCINES AGAINST HIV-AIDS: 2011 - IX Jornada de promoci³ de la](https://reader031.vdocuments.us/reader031/viewer/2022012011/613d3931736caf36b75ac863/html5/thumbnails/45.jpg)
100 %
100 %
vacuna
Vacuna AIDSVax
![Page 46: VACCINES AGAINST HIV-AIDS: 2011 - IX Jornada de promoci³ de la](https://reader031.vdocuments.us/reader031/viewer/2022012011/613d3931736caf36b75ac863/html5/thumbnails/46.jpg)
![Page 47: VACCINES AGAINST HIV-AIDS: 2011 - IX Jornada de promoci³ de la](https://reader031.vdocuments.us/reader031/viewer/2022012011/613d3931736caf36b75ac863/html5/thumbnails/47.jpg)
Adenovirus
![Page 48: VACCINES AGAINST HIV-AIDS: 2011 - IX Jornada de promoci³ de la](https://reader031.vdocuments.us/reader031/viewer/2022012011/613d3931736caf36b75ac863/html5/thumbnails/48.jpg)
Buchbinder Lancet 2008
![Page 49: VACCINES AGAINST HIV-AIDS: 2011 - IX Jornada de promoci³ de la](https://reader031.vdocuments.us/reader031/viewer/2022012011/613d3931736caf36b75ac863/html5/thumbnails/49.jpg)
![Page 50: VACCINES AGAINST HIV-AIDS: 2011 - IX Jornada de promoci³ de la](https://reader031.vdocuments.us/reader031/viewer/2022012011/613d3931736caf36b75ac863/html5/thumbnails/50.jpg)
> 99 %
![Page 51: VACCINES AGAINST HIV-AIDS: 2011 - IX Jornada de promoci³ de la](https://reader031.vdocuments.us/reader031/viewer/2022012011/613d3931736caf36b75ac863/html5/thumbnails/51.jpg)
100 %
100 %
vacuna Vacuna MSD: Step trial
![Page 52: VACCINES AGAINST HIV-AIDS: 2011 - IX Jornada de promoci³ de la](https://reader031.vdocuments.us/reader031/viewer/2022012011/613d3931736caf36b75ac863/html5/thumbnails/52.jpg)
Rolland et al, Nat Med. 2011
Infecting HIV sequences Gag sequences differ genetically from
sequences contained in the vaccine
Gag Pol Nef Nef Pol Gag
![Page 53: VACCINES AGAINST HIV-AIDS: 2011 - IX Jornada de promoci³ de la](https://reader031.vdocuments.us/reader031/viewer/2022012011/613d3931736caf36b75ac863/html5/thumbnails/53.jpg)
STEP trial post-analyses
• Viruses in breakthrough infections (i.e. in vaccine group) are genetically further
apart from the vaccine sequence than viruses in the placebo-group
• This “sieve-effect” suggests that:
• the vaccine may have blocked the out-growth of HIV variants that were
most similar to the vaccine
• the vaccine induced immune response may have driven specific viral
evolution
• The differences in viral evolution or strain selection did NOT affect viral load, but
the observed selection effect indicates that the induced immunity was in some
way acting on the virus at least.
![Page 54: VACCINES AGAINST HIV-AIDS: 2011 - IX Jornada de promoci³ de la](https://reader031.vdocuments.us/reader031/viewer/2022012011/613d3931736caf36b75ac863/html5/thumbnails/54.jpg)
![Page 55: VACCINES AGAINST HIV-AIDS: 2011 - IX Jornada de promoci³ de la](https://reader031.vdocuments.us/reader031/viewer/2022012011/613d3931736caf36b75ac863/html5/thumbnails/55.jpg)
RV144 / “Thai trial”
![Page 56: VACCINES AGAINST HIV-AIDS: 2011 - IX Jornada de promoci³ de la](https://reader031.vdocuments.us/reader031/viewer/2022012011/613d3931736caf36b75ac863/html5/thumbnails/56.jpg)
Poxvirus (ALVAC)
![Page 57: VACCINES AGAINST HIV-AIDS: 2011 - IX Jornada de promoci³ de la](https://reader031.vdocuments.us/reader031/viewer/2022012011/613d3931736caf36b75ac863/html5/thumbnails/57.jpg)
Viral envelope
gp41
CD4bs
gp120
(Burton D. Human neutralizing antibodies and a vaccine for HIV-1.
XIV International AIDS Conference [Abstract nº201])
dominio de fusión
dominio interacción CD4
![Page 58: VACCINES AGAINST HIV-AIDS: 2011 - IX Jornada de promoci³ de la](https://reader031.vdocuments.us/reader031/viewer/2022012011/613d3931736caf36b75ac863/html5/thumbnails/58.jpg)
Total of 16402 individuals enrolled between vaccine and placebo group
![Page 59: VACCINES AGAINST HIV-AIDS: 2011 - IX Jornada de promoci³ de la](https://reader031.vdocuments.us/reader031/viewer/2022012011/613d3931736caf36b75ac863/html5/thumbnails/59.jpg)
Is there an early effect on HIV acquisition ?
P=0.01
Rerks-Ngarm NEJM 2009
![Page 60: VACCINES AGAINST HIV-AIDS: 2011 - IX Jornada de promoci³ de la](https://reader031.vdocuments.us/reader031/viewer/2022012011/613d3931736caf36b75ac863/html5/thumbnails/60.jpg)
> 99 %
![Page 61: VACCINES AGAINST HIV-AIDS: 2011 - IX Jornada de promoci³ de la](https://reader031.vdocuments.us/reader031/viewer/2022012011/613d3931736caf36b75ac863/html5/thumbnails/61.jpg)
100 %
30 % 70 %
vacuna Thai trial RV144
![Page 62: VACCINES AGAINST HIV-AIDS: 2011 - IX Jornada de promoci³ de la](https://reader031.vdocuments.us/reader031/viewer/2022012011/613d3931736caf36b75ac863/html5/thumbnails/62.jpg)
Post RV144 analyses
Barton Haynes, Bangkok AIDS Vaccine 2011, Sept 13th
![Page 63: VACCINES AGAINST HIV-AIDS: 2011 - IX Jornada de promoci³ de la](https://reader031.vdocuments.us/reader031/viewer/2022012011/613d3931736caf36b75ac863/html5/thumbnails/63.jpg)
Broadly Cross-Neutralizing Antibodies in HIV-1 Patients with Undetectable Viremia. Medina-Ramírez et al, J. Virology, in
press
V1 191 (A) NL4-3 (B) AC10 (B) 92BR025 (C) 92UG024 (D) CM244 (E) VSV
528-010 49.1±11.3 1.7±0.9 13.4±2.7 6.8±3.0 7.1±5.3 13.8±1.1 67.1±2.2
734-000 17.9±3.7 0.1±0.3 28.0±5.1 2.1±1.0 21.4±9.6 38.9±3.9 58.7±2.6
521-005 26.3±7.1 2.1±1.4 27.1±2.7 30.8±4.7 23.3±2.9 16.6±1.0 70.0±2.4
600-003 28.6±3.5 3.1±0.7 44.2±8.2 13.1±5.0 42.5±21.9 22.9±0.8 54.1±6.6
363-014 26.7±14.4 2.4±0.3 15.9±3.7 14.8±0.4 35.5±18.4 24.4±2.5 50.5±3.3
541-011 34.9±4.0 4.5±0.5 40.6±6.0 26.3±1.8 46.4±2.7 48.5±2.7 62.6±4.8
181-036 40.6±10.2 14.6±3.1 46.6±1.3 26.2±10.5 43.5±18.6 27.6±3.3 94.2±14.2
488-013 16.9±1.9 1.2±0.8 48.7±9.9 13.9±2.3 36.7±18.1 46.9±2.6 77.9±4.4
642-007 27.8±9.8 3.7±2.7 16.7±2.7 27.7±7.5 44.6±7.4 26.9±3.5 96.5±2.2
308-031 17.5±1.4 1.7±1.2 9.1±4.4 9.1±2.2 20.8±3.6 33.0±6.2 85.7±4.5
331-030 32.4±2.4 5.8±0.7 25.0±6.6 14.7±2.6 38.5±3.7 42.8±5.9 63.7±9.1
634-005 44.2±6.0 6.0±6.7 45.1±12.0 42.4±9.2 49.5±11.4 23.8±1.9 103.15.9
![Page 64: VACCINES AGAINST HIV-AIDS: 2011 - IX Jornada de promoci³ de la](https://reader031.vdocuments.us/reader031/viewer/2022012011/613d3931736caf36b75ac863/html5/thumbnails/64.jpg)
Viral envelope
gp41
CD4bs
gp120
(Burton D. Human neutralizing antibodies and a vaccine for HIV-1.
XIV International AIDS Conference [Abstract nº201])
dominio de fusión
dominio interacción CD4
![Page 65: VACCINES AGAINST HIV-AIDS: 2011 - IX Jornada de promoci³ de la](https://reader031.vdocuments.us/reader031/viewer/2022012011/613d3931736caf36b75ac863/html5/thumbnails/65.jpg)
> 99 %
![Page 66: VACCINES AGAINST HIV-AIDS: 2011 - IX Jornada de promoci³ de la](https://reader031.vdocuments.us/reader031/viewer/2022012011/613d3931736caf36b75ac863/html5/thumbnails/66.jpg)
100 %
30 % 70 %
vacuna
Thai trial RV144
![Page 67: VACCINES AGAINST HIV-AIDS: 2011 - IX Jornada de promoci³ de la](https://reader031.vdocuments.us/reader031/viewer/2022012011/613d3931736caf36b75ac863/html5/thumbnails/67.jpg)
100 %
90 % 10 %
vacuna Vacuna HIVACAT ??
![Page 68: VACCINES AGAINST HIV-AIDS: 2011 - IX Jornada de promoci³ de la](https://reader031.vdocuments.us/reader031/viewer/2022012011/613d3931736caf36b75ac863/html5/thumbnails/68.jpg)
HIVACAT Second Period HIVACAT Current Period
2012 2013 2014 2015 2016 2011
69
DNA Vectors Murine analysis, immunogenicity & GMP + Toxicology
Phase I clinical trial
VLP
Timelines Prophylactic Vaccines
BCG Vectors: rBCG:HIVA
Vector devel. Clade A murine analysis & toxicology
rBCG-2auxo-HIVconsv, -HIVACAT T-cell, -malaria+TB
BCG - synthesis vector for VLPs
Prime/boost
T and B cell immunogens in:
GMP + Toxicology
Phase I clinical trial
MVA Vectors
Cloning & expression, Murine analysis & immunogenicity
HSP Vectors
Loading & representation
Murine analysis, immunogenicity & GMP +Toxicology
Phase I clinical trial
RISVAC02- MVA Phase II clinical trial
Phase I clinical trial & trial data
Murine analysis, immunogenicity & GMP +Toxic<ology
Phase I clinical trial
Construction, stability & imm.
![Page 69: VACCINES AGAINST HIV-AIDS: 2011 - IX Jornada de promoci³ de la](https://reader031.vdocuments.us/reader031/viewer/2022012011/613d3931736caf36b75ac863/html5/thumbnails/69.jpg)
HIVACAT Second Period HIVACAT Current Period
2012 2013 2014 2015 2016 2011
70
New neutralizing Ab Isolation of human monoclonal Ab
Immunogen design for nAb
Library of mutant Env proteins
Ab secreting cells in STI Patients screening
Selected Env Seq. / nAb Refinement 1s t gen. B cell imm. & 2nd gen. B cell imm.
Timelines B cell immunogen
gp41 immunogens Murine & stability analysis
Design optimized strat. human immunization
Selection, phenotypic characterization and immunogenicity Studies of selected variants
Neutralization as.
nAb identification
Immunogenicity
![Page 70: VACCINES AGAINST HIV-AIDS: 2011 - IX Jornada de promoci³ de la](https://reader031.vdocuments.us/reader031/viewer/2022012011/613d3931736caf36b75ac863/html5/thumbnails/70.jpg)
VACCINES AGAINST HIV-AIDS: 2011
1. General considerations
2. Therapeutic vaccines against HIV. Dendritic cells 3. Preventive vaccines against HIV. Other strategies for
prevention
4. Final considerations
![Page 71: VACCINES AGAINST HIV-AIDS: 2011 - IX Jornada de promoci³ de la](https://reader031.vdocuments.us/reader031/viewer/2022012011/613d3931736caf36b75ac863/html5/thumbnails/71.jpg)
clinicaloptions.com/hiv
HIV/AIDS Highlights From Rome
Efficacy of HIV Prevention Strategies From
Randomized Clinical Trials
Abdool Karim SS, et al. Lancet. 2011;[Epub ahead of print].
100 0 20 40 60 80
Efficacy (%)
Study Effect Size, % (95% CI)
ART for prevention; HPTN 052, Africa, Asia, Americas
PrEP for discordant couples; Partners PrEP, Uganda, Kenya
PrEP for heterosexual men and women; TDF2, Botswana
Medical male circumcision; Orange Farm, Rakai, Kisumu
PrEP for MSMs; iPrEX, Americas, Thailand, South Africa
Sexually transmitted diseases treatment; Mwanza, Tanzania
Microbicide; CAPRISA 004, South Africa
HIV vaccine; RV144, Thailand
96 (73-99)
73 (49-85)
63 (21-84)
54 (38-66)
44 (15-63)
42 (21-58)
39 (6-60)
31 (1-51)
![Page 72: VACCINES AGAINST HIV-AIDS: 2011 - IX Jornada de promoci³ de la](https://reader031.vdocuments.us/reader031/viewer/2022012011/613d3931736caf36b75ac863/html5/thumbnails/72.jpg)
The Research Centres
73
Two internationally renowned centres of reference More than 60 investigators
Program Directors Scientific Dr
HIVACAT Strategic Committee